Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696260 | 0.84 | SERPINE1 (0.43) | ALDH1A1ALOX15SMN1; SMN2MAPTKDM4E | |
| SCHEMBL30524282 | 0.84 | SERPINE1 (0.43) | ALDH1A1ALOX15SMN1; SMN2MAPTKDM4E | |
| SCHEMBL18697277 | 0.82 | FAAH (0.49) | ALDH1A1ALOX15FAAHSMN1; SMN2MAPT | |
| SCHEMBL29585912 | 0.82 | FAAH (0.49) | ALDH1A1ALOX15FAAHSMN1; SMN2MAPT | |
| SCHEMBL57243 | 0.82 | FAAH (0.49) | ALDH1A1ALOX15FAAHSMN1; SMN2MAPT | |
| SCHEMBL2940941 | 0.82 | FAAH (0.49) | ALDH1A1ALOX15FAAHSMN1; SMN2MAPT | |
| SCHEMBL6966435 | 0.80 | FAAH (0.47) | ALDH1A1ALOX15FAAHSMN1; SMN2MAPT | |
| SCHEMBL57244 | 0.80 | FAAH (0.51) | ALDH1A1FAAHSMN1; SMN2MAPTPARP10 | |
| SCHEMBL2830676 | 0.79 | CES2 (0.45) | FAAHMAPTKDM4EKMT2ACES2 | |
| SCHEMBL2322496 | 0.78 | PARP10 (0.53) | ALDH1A1FAAHSMN1; SMN2MAPTPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654968-A1 | PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF | Alivus Life Sciences Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024157170-A1 | PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF | GLENMARK LIFE SCIENCES LIMITED (IN) | 2024-08-02 | — | — | WO | disclosed |
| CN-116940576-A | Method for producing S, S- (6-methylquinoxaline-2, 3-diyl) dithiocarbonate | 株式会社大阪曹达 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022202643-A1 | METHOD FOR PRODUCING S,S-(6-METHYLQUINOXALINE-2,3-DIYL)DITHIOCARBONATE | 株式会社大阪ソーダ | 2022-09-29 | — | — | WO | disclosed |
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-9346786-B2 | Pyrrolidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9226916-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150266856-A1 | RORGamma Modulators | EXELIXIS, INC. | 2015-09-24 | — | — | US | disclosed |
| EP-2513084-B1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20060194841-A1 | E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1650189-A1 | BENZYLAMINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | NOVO NORDISK A/S (DK) | 2002-06-27 | — | — | US | disclosed |
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | disclosed |
| US-5843983-A | Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| US-5811424-A | CONTROL OF DOWNY MILDEW, LATE BLIGHT | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0790235-A1 | Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses | SANKYO COMPANY LIMITED (JP) | 1997-08-20 | — | — | EP | disclosed |
| US-4376731-A | 2-NITRILES THEREOF | BOEHRINGER MANNHEIM GMBH (DE) | 1983-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266856-A1 | RORGamma Modulators | RORB, RORA, RORC | ALDH1A1 1877/4885ALOX15 2259/4885FAAH 3398/4885 |
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | ALDH1A1 1669/4885ALOX15 1003/4885FAAH 3187/4885 |
| US-20060194841-A1 | E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting | KCNAB1, BDKRB2, ARRB1 | ALDH1A1 1065/4885ALOX15 2584/4885FAAH 942/4885 |
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | FABP1, FFAR2, FFAR1 | ALDH1A1 779/4885ALOX15 103/4885FAAH 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.